ADMA Biologics Sees Unusually Large Options Volume (NASDAQ:ADMA)

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of unusually large options trading on Monday. Stock traders bought 11,474 call options on the stock. This represents an increase of approximately 539% compared to the typical volume of 1,797 call options.

ADMA Biologics Trading Down 0.6 %

ADMA Biologics stock opened at $22.48 on Tuesday. The stock has a market cap of $5.24 billion, a PE ratio of 80.29 and a beta of 0.64. The stock has a 50-day moving average price of $18.12 and a 200 day moving average price of $13.95. ADMA Biologics has a 52 week low of $3.60 and a 52 week high of $23.64. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 59.29% and a net margin of 17.80%. During the same quarter last year, the business posted $0.01 EPS. Equities research analysts predict that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

Insider Transactions at ADMA Biologics

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now owns 241,441 shares of the company’s stock, valued at $4,408,712.66. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock worth $8,224,121 over the last 90 days. 3.70% of the stock is currently owned by insiders.

Institutional Trading of ADMA Biologics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADMA. Bank of Montreal Can purchased a new stake in ADMA Biologics during the 2nd quarter worth about $17,886,000. D. E. Shaw & Co. Inc. grew its holdings in ADMA Biologics by 26.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after buying an additional 1,442,799 shares during the period. Principal Financial Group Inc. grew its holdings in ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after buying an additional 1,059,394 shares during the period. Castleark Management LLC purchased a new stake in ADMA Biologics in the 1st quarter valued at about $5,400,000. Finally, First Turn Management LLC purchased a new stake in ADMA Biologics in the 3rd quarter valued at about $13,293,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ADMA. Raymond James raised their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday. HC Wainwright raised their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.